Quince Therapeutics regains Nasdaq $1 minimum bid price compliance
Share
Listen to the news
Quince Therapeutics regains Nasdaq $1 minimum bid price compliance
  • Quince Therapeutics regained compliance with Nasdaq minimum bid price rule 5450(a)(1) following 10 straight sessions with a closing bid at or above $1 from April 13 through April 24.
  • Nasdaq closed bid-price deficiency matter in a letter dated April 27.
  • Market value of listed securities deficiency under Nasdaq rule 5450(b)(2)(A) remains unresolved, with $50 million minimum required for Nasdaq Global Select Market.
  • Company has until Sept. 14, 2026 to regain compliance with market value requirement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-187243), on April 28, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending